()-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3,4,5-Trimethoxyphenyl)allyl)-1-1,2,4-Triazole and Related Compounds: Their Synthesis and Biological Evaluation As Novel Antimitotic Agents Targeting Breast Cancer

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Date 2025 Jan 25

PMID 39861179

Authors

Gloria Ana

Azizah M Malebari

Sara Noorani

Darren Fayne

Niamh M OBoyle

Daniela M Zisterer

Elisangela Flavia Pimentel

Denise Coutinho Endringer

Mary J Meegan

Affiliations

Soon will be listed here.

Abstract

The synthesis of ()-1-(1,3-diphenylallyl)-1-1,2,4-triazoles and related compounds as anti-mitotic agents with activity in breast cancer was investigated. These compounds were designed as hybrids of the microtubule-targeting chalcones, indanones, and the aromatase inhibitor letrozole. : A panel of 29 compounds was synthesized and examined by a preliminary screening in estrogen receptor (ER) and progesterone receptor (PR)-positive MCF-7 breast cancer cells together with cell cycle analysis and tubulin polymerization inhibition. : ()-5-(3-(1-1,2,4-triazol-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)-2-methoxyphenol was identified as a potent antiproliferative compound with an IC value of 0.39 mM in MCF-7 breast cancer cells, 0.77 mM in triple-negative MDA-MB-231 breast cancer cells, and 0.37 mM in leukemia HL-60 cells. In addition, compound demonstrated potent activity in the sub-micromolar range against the NCI 60 cancer cell line panel including prostate, melanoma, colon, leukemia, and non-small cell lung cancers. G/M phase cell cycle arrest and the induction of apoptosis in MCF-7 cells together with inhibition of tubulin polymerization were demonstrated. Immunofluorescence studies confirmed that compound targeted tubulin in MCF-7 cells, while computational docking studies predicted binding conformations for in the colchicine binding site of tubulin. Compound also selectively inhibited aromatase. : Based on the results obtained, these novel compounds are suitable candidates for further investigation as antiproliferative microtubule-targeting agents for breast cancer.

References

Ana G, Kelly P, Malebari A, Noorani S, Nathwani S, Twamley B . Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1-1,2,4-triazoles and 1-(Diarylmethyl)-1-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer. Pharmaceuticals (Basel). 2021; 14(2). PMC: 7926793. DOI: 10.3390/ph14020169. View

Huang X, Huang R, Li L, Gou S, Wang H . Synthesis and biological evaluation of novel chalcone derivatives as a new class of microtubule destabilizing agents. Eur J Med Chem. 2017; 132:11-25. DOI: 10.1016/j.ejmech.2017.03.031. View

Negi A, Gautam Y, Alam S, Chanda D, Luqman S, Sarkar J . Natural antitubulin agents: importance of 3,4,5-trimethoxyphenyl fragment. Bioorg Med Chem. 2015; 23(3):373-89. DOI: 10.1016/j.bmc.2014.12.027. View

Burstein H, Somerfield M, Barton D, Dorris A, Fallowfield L, Jain D . Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021; 39(35):3959-3977. PMC: 8659999. DOI: 10.1200/JCO.21.01392. View

Singh A, Fatima K, Singh A, Behl A, Mintoo M, Hasanain M . Anticancer activity and toxicity profiles of 2-benzylidene indanone lead molecule. Eur J Pharm Sci. 2015; 76:57-67. DOI: 10.1016/j.ejps.2015.04.020. View

Ducki S . Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. Anticancer Agents Med Chem. 2009; 9(3):336-47. DOI: 10.2174/1871520610909030336. View

Gobbi S, Martini S, Rozza R, Spinello A, Caciolla J, Rampa A . Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment. Molecules. 2023; 28(7). PMC: 10096035. DOI: 10.3390/molecules28073047. View

Tang C, Li C, Zhang S, Hu Z, Wu J, Dong C . Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer. J Med Chem. 2015; 58(11):4550-72. DOI: 10.1021/acs.jmedchem.5b00099. View

Lv W, Liu J, Lu D, Flockhart D, Cushman M . Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem. 2013; 56(11):4611-8. PMC: 4043309. DOI: 10.1021/jm400364h. View

10.

Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J . Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem. 2009; 17(6):2623-31. DOI: 10.1016/j.bmc.2008.10.044. View

11.

Pettit G, Toki B, Herald D, Verdier-Pinard P, Boyd M, Hamel E . Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem. 1998; 41(10):1688-95. DOI: 10.1021/jm970644q. View

12.

Woo L, Bubert C, Purohit A, Potter B . Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. ACS Med Chem Lett. 2014; 2(3):243-7. PMC: 4018047. DOI: 10.1021/ml100273k. View

13.

Caciolla J, Martini S, Spinello A, Pavlin M, Turrini E, Simonelli F . Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer. Eur J Med Chem. 2021; 224:113733. DOI: 10.1016/j.ejmech.2021.113733. View

14.

Goldenberg D, Sharkey R . Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019; 11(6):987-995. PMC: 6748572. DOI: 10.1080/19420862.2019.1632115. View

15.

Stresser D, Turner S, McNamara J, Stocker P, Miller V, Crespi C . A high-throughput screen to identify inhibitors of aromatase (CYP19). Anal Biochem. 2000; 284(2):427-30. DOI: 10.1006/abio.2000.4729. View

16.

Drutovic D, Chripkova M, Pilatova M, Kruzliak P, Perjesi P, Sarissky M . Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells. Tumour Biol. 2014; 35(10):9967-75. DOI: 10.1007/s13277-014-2289-y. View

17.

Vale N, Silva S, Duarte D, Crista D, da Silva L, da Silva J . Normal breast epithelial MCF-10A cells to evaluate the safety of carbon dots. RSC Med Chem. 2021; 12(2):245-253. PMC: 8128052. DOI: 10.1039/d0md00317d. View

18.

Tian G, Song Q, Liu Z, Guo J, Cao S, Long S . Recent advances in 1,2,3- and 1,2,4-triazole hybrids as antimicrobials and their SAR: A critical review. Eur J Med Chem. 2023; 259:115603. DOI: 10.1016/j.ejmech.2023.115603. View

19.

Pereira D, Duraes F, Szemeredi N, Freitas-da-Silva J, Pinto E, Martins-da-Costa P . New Chalcone-Triazole Hybrids with Promising Antimicrobial Activity in Multidrug Resistance Strains. Int J Mol Sci. 2022; 23(22). PMC: 9697807. DOI: 10.3390/ijms232214291. View

20.

Lazinski L, Royal G, Robin M, Maresca M, Haudecoeur R . Bioactive Aurones, Indanones, and Other Hemiindigoid Scaffolds: Medicinal Chemistry and Photopharmacology Perspectives. J Med Chem. 2022; 65(19):12594-12625. DOI: 10.1021/acs.jmedchem.2c01150. View